Mr. Tindall has extensive leadership experience as a Board Chairman, CEO, Executive and Founder of life sciences companies across multiple therapeutic modalities and domains including, rare disease, cardiovascular disease, neurology, oncology, infectious disease and bioinformatics.

Over the past two decades, Mr. Tindall led teams at Fabric Genomics (acquired by GeneDx), IMS Health (now IQVIA), Digitas Health, Wheatsheaf Group (now Grosvenor), Genzyme Corporation (acquired by Sanofi), Celera Genomics and Eli Lilly & Company.

Mr. Tindall currently participates as a Board Director and Co-founder at Coronation Bio and as a Co-founder at Kodikaz Therapeutic Solutions.